PROFILING CIRCULATING DNA AND RNA TO IDENTIFY MECHANISMS OF THERAPEUTIC RESISTENCE AND RESPONSE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Grant number: 1098647 | Funding period: 2018 - 2020

Completed

Abstract

Enzalutamide is a powerful hormone treatment that improves survival for men with advanced prostate cancer. Unfortunately, all prostate cancers eventually become resistant to enzalutamide and not all men initially respond to treatment. I will look for blood markers that predict which men benefit from enzalutamide treatment and try to understand how resistance to enzalutamide occurs. This may lead to more effective use of enzalutamide resulting in better outcomes in advanced prostate cancer.

Researchers